News

The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as a dependency transcription factor…

To inhibit or to degrade? For certain cancer drug targets, like Aurora Kinase A (AURKA), protein degradation may be beneficial and offer a more targeted-therapeutic approach compared to the use…

Onderzoekers van de vakgroep Biomoleculaire Geneeskunde hebben ontdekt hoe patiënten een hoog-risico neuroblastoom ontwikkelen. Door twee bestaande medicijnen te combineren, zou deze vorm van kinderkanker in de toekomst beter behandeld…

Wil je meer weten over het belang van zebravissen in het onderzoek naar neuroblastoom? Lees dan het interview met prof. dr. Kaat Durinck!

Want to know more on how copy number changes shape neuroblastoma biology, check out our new review in the latest issue of Journal of Personalized Medicine: “From DNA Copy Number Gains…

MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. Our discovery efforts focused on identifying cooperating interactors and vulnerabilities in the MYCN regulatory network. MYCN-driven neuroblastomas can…

CONGRATULATIONS!! Joshua Goulding (PhD student) received a VAGABOND medal for the best poster presentation and defense during the VAGABOND summer school event. 

With the support of the Olivia Hendrickx Research Fund , the ‘Team EARly DRug development in Paediatric oncology (TEARDRoP)’ consortium was founded. As the name indicates, this consortium was set up to…